Vivian Bykerk, MD, associate attending rheumatologist at HSS, associate professor of medicine at Weill Cornell Medical College discusses new treatments in inflammatory disease.
Transcript
What are some new directions in treating inflammatory diseases that you’re particularly excited about?
So, the first, I guess, and it’s not that new, is early diagnosis. It’s a way to classify the disease sooner than later, having a blood test to be able to do so in a number of people, though not all. Also, part of it is having people understand that the expectation is to get people into remission in the first year, and then, keep them there, as sort of new standards and new guidelines. Another part of it is the translational side of it. There’s a huge effort to now try and understand how the tissue in the rheumatoid joint is functioning in terms of cell-cell interactions, and sending things in and out of the blood to get a new understanding of how the tissue functions to perpetuate the disease and even start the disease. We don’t think it starts in the joint. We think it starts in the mucosa and something travels to the joint, but we don’t know why. And then a whole interaction of cells comes, and they have a party, basically, and they start to work with each other to build what is more like a benign tumor in the joint, and that, in and of itself, is very destructive.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.